Seagen®

SEA-CD40

An investigational sugar-engineered antibody directed to CD40



Key Attributes

- Humanized, nonfucosylated IgG1 monoclonal antibody[1,2]
- Increased affinity for activating FcγRIIIa and minimal affinity for inhibitory FcγRIIb[3,4]
- Binding to FcγRIIIa confers enhanced Fc-mediated effector function[3,4]

Target: CD40

- An immune-activating cell surface receptor of the TNFR superfamily[1,2,5]
- Expressed on APCs and by a wide range of tumor types[5]
- Activation requires binding to CD40L and receptor clustering known as "agonism"[3,6]
- Agonism induces cytokine/chemokine production and upregulation of costimulatory receptors[3,6]

Proposed Mechanism of Action[6,7,a]

- Agonism and enhanced antigen uptake by APCs
- Generation of antigen-specific memory T cells

APC: antigen-presenting cell; **IgG1**: immunoglobulin G1; **TNFR**: tumor necrosis factor receptor

[a] Based on preclinical data.

1. Gardai SJ, et al. *Cancer Res*. 2015;75(Suppl 15):Abstract 2472. **2**. Grilley-Olson JE, et al. *J Clin Oncol*. 2018;36(Suppl 15):3093. **3**. Gardai SJ, et al. *Cancer Res*. 2016;76(Suppl 14):Abstract 4994. **4**. Zeng W, et al. Poster presented at: SITC; Nov 2020; Virtual. Poster 438. **5**. Piechutta M, et al. *ESMO Open*. 2019;4:e000510. **6**. Vonderheide RH, et al. *Clin Cancer Res*. 2013;19(5):1035-1043. **7**. Neff-LaFord H, et al. Poster presented at: AACR; Apr and Jun 2020; Virtual. Poster 5535.

SEA-CD40

Seagen®

Proposed Mechanism of Action[1,2,a]

1. Binding of SEA-CD40 to CD40 and FcγRIIIa results in amplified agonism on APCs and NK cells
2. Selective binding of SEA-CD40 to activating Fc receptors drives a second activation signal to APCs
3. Antigen-specific memory T cells are activated, which target and kill tumor cells
4. Antigens released during tumor cell death amplify immune response



APC: antigen-presenting cell; **NK**: natural killer

1. Zeng W, et al. Poster presented at: SITC; Nov 2020; Virtual. Poster 438. **2**. Neff-LaFord H, et al. Poster presented at: AACR; Apr and Jun 2020; Virtual. Poster 5535.

Clinical Trials[a]

Phase 1 · Phase 2 · Phase 3

RECRUITING	**SGNS40-002: Melanoma and NSCLC** (NCT04993677) SEA-CD40 + pembrolizumab + pemetrexed + carboplatin (NSCLC arm) SEA-CD40 + pembrolizumab (melanoma arm)
ACTIVE, NOT RECRUITING	**SGNS40-001: Advanced solid tumors and lymphomas** (NCT02376699) SEA-CD40 ± anti-PD1 ± chemotherapy

NSCLC: non–small cell lung cancer

[a] Based on preclinical data.

Clinical trial information retrieved from clinicaltrials.gov, accessed October 2022.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Printed in the USA USM/S40/2022/0008

For more information, contact us at:
+1-855-4SEAGEN (+1-855-473-2436)
medinfo@seagen.com / medinfoEU@seagen.com
www.seagenmedinfo.com